Table 5. IC50 Values (μM) Determined for the Diruthenium Complexes (2b, 3a, 3b and 3c) and Reference Compounds (RAPTA-C and Cisplatin) on Human Ovarian Carcinoma (A2780), Cisplatin-Resistant Human Ovarian Carcinoma (A2780cisR), Breast Adenocarcinoma (MCF-7), Human Osteosarcoma (HOS), Human Lung Adenocarcinoma (A549), Human Pancreatic Carcinoma (PANC-1), Human Colorectal Adenocarcinoma (Caco-2), Human Prostate Carcinoma (PC-3), Human Cervical Carcinoma (HeLa), and Normal Human Lung Fibroblast (MRC-5) Cell Linesa.
| A2780 | A2780R | MCF-7 | HOS | A549 | PANC-1 | Caco-2 | PC-3 | HeLa | MRC-5 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2b | 6.2 ± 1.2 | 7.3 ± 2.4 | 19.0 ± 4.5 | 24.0 ± 3.8 | >50 | >50 | >50 | 36.0 ± 4.1 | 5.5 ± 0.9 | >50 |
| 3a | 4.2 ± 0.9 | 6.4 ± 1.9 | 16.2 ± 1.7 | 14.6 ± 0.5 | 25.3 ± 1.9 | 28.4 ± 3.9 | >50 | 22.2 ± 2.4 | 17.5 ± 2.9 | 38.3 ± 3.9 |
| 3b | 3.4 ± 0.6 | 4.6 ± 1.3 | 11.6 ± 1.5 | 12.6 ± 0.5 | 16.1 ± 1.3 | 19.8 ± 2.3 | 36.0 ± 2.7 | 13.4 ± 1.8 | 12.5 ± 1.1 | 25.9 ± 2.9 |
| 3c | 6.3 ± 1.3 | 11.7 ± 2.4 | 22.0 ± 4.0 | 17.7 ± 2.8 | 20.7 ± 1.4 | 30.0 ± 0.6 | 42.8 ± 0.8 | 19.6 ± 3.7 | 16.3 ± 1.3 | 21.5 ± 4.0 |
| RAPTA-C | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 |
| cisplatin | 15.2 ± 1.1 | 40.0 ± 3.9 | 28.4 ± 2.7 | 26.3 ± 3.3 | 39.2 ± 3.1 | >50 | >50 | >50 | 30.7 ± 0.6 | >50 |
a
Incubation time = 24 h. The values are presented as the mean ± the standard deviation (SD).